Interleukin-10 Reduces Neurogenic Inflammation and Pain Behavior in a Mouse Model of Type 2 Diabetes

Yanik, Brandon M.; Dauch, Jacqueline R.; Cheng, Hong

doi:10.2147/jpr.s264136

Cited by 19 publications

(10 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(37) It protects the nerve by reducing neuroinflammation apoptosis via NF-κB suppression promoting tissue recovery such as axon regeneration and improving of motor and sensory function. (38,39) However, thymoquinone administration in our study decreases the IL-10 level instead of increasing it. The previous study's finding might explain our results.…”

Section: Resultsmentioning

confidence: 57%

Thymoquinone Modulates Local MMP-9, IL-10, and IgG in Sciatic Nerve Crush Injury Animal Model

et al. 2022

View full text Add to dashboard Cite

BACKGROUND: Interleukin (IL)-10 is involved in Wallerian degeneration after peripheral nerve crush injury. Oral thymoquinone was previously observed to decrease local immunoglobulin-G (IgG) in a crush-injured rat model. No study has evaluated the pathway of various thymoquinone dosages on local IgG and IL-10 in this injury.METHODS: This experimental study used 126 Rattus norvegicus Wistar rats that were divided into 18 groups: six groups received a placebo, the other six groups received thymoquinone at 100 mg/kg/day and the last six groups received thymoquinone at 250 mg/kg/day, respectively. Rats were sacrificed at 12, 18, 24, 5x24, 6x24, and 7x24 hours. Matrix metalloproteinase-9 (MMP-9), IL-10, and local IgG levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). The nuclear factor KappaB (NF-κB) expressions on Schwann cells were examined by flow cytometry. Path analysis was performed using SmartPLS.RESULTS: The path analysis showed that 100mg/kg/day of thymoquinone significantly decreased NF-κB expression. However, NF-κB did not affect local MMP-9, and MMP-9 had no significant relationship with local IL-10 and IgG. Thymoquinone 250 mg/kg/day also significantly inhibited NF-kB expression, decreased local MMP-9, and, in turn, decreased local IL-10 and IgG.CONCLUSION: Administration of oral thymoquinone 250 mg/kg/day decreases local IgG and IL-10 levels via suppressing NF-κB expression and MMP-9 leveKEYWORDS: thymoquinone, crush injury, IgG, IL-10, MMP-9, NF-κB

show abstract

Section: Resultsmentioning

confidence: 57%

Thymoquinone Modulates Local MMP-9, IL-10, and IgG in Sciatic Nerve Crush Injury Animal Model

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Protective functions in the pathogenesis of neuropathy have been attributed to IL-10. It is a conventional anti-inflammatory alternative polarity marker [12,83,84] and intrathecal administration of recombinant IL-10 reverses both mechanical and thermal hypersensitivity following nerve damage [85,86]. Additionally, IL-1RA and IL-18BP are important macrophage/microglia and astrocyte alternative polarization markers [12].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model—In Vivo and In Vitro Study

Piotrowska

Ciapała

Pawlik

et al. 2021

IJMS

View full text Add to dashboard Cite

Recent findings have highlighted the roles of CXC chemokine family in the mechanisms of neuropathic pain. Our studies provide evidence that single/repeated intrathecal administration of CXCR2 (NVP-CXCR2-20) and CXCR3 ((±)-NBI-74330) antagonists explicitly attenuated mechanical/thermal hypersensitivity in rats after chronic constriction injury of the sciatic nerve. After repeated administration, both antagonists showed strong analgesic activity toward thermal hypersensitivity; however, (±)-NBI-74330 was more effective at reducing mechanical hypersensitivity. Interestingly, repeated intrathecal administration of both antagonists decreased the mRNA and/or protein levels of pronociceptive interleukins (i.e., IL-1beta, IL-6, IL-18) in the spinal cord, but only (±)-NBI-74330 decreased their levels in the dorsal root ganglia after nerve injury. Furthermore, only the CXCR3 antagonist influenced the spinal mRNA levels of antinociceptive factors (i.e., IL-1RA, IL-10). Additionally, antagonists effectively reduced the mRNA levels of pronociceptive chemokines; NVP-CXCR2-20 decreased the levels of CCL2, CCL6, CCL7, and CXCL4, while (±)-NBI-74330 reduced the levels of CCL3, CCL6, CXCL4, and CXCL9. Importantly, the results obtained from the primary microglial and astroglial cell cultures clearly suggest that both antagonists can directly affect the release of these ligands, mainly in microglia. Interestingly, NVP-CXCR2-20 induced analgesic effects after intraperitoneal administration. Our research revealed important roles for CXCR2 and CXCR3 in nociceptive transmission, especially in neuropathic pain.

show abstract

“…The condition affects a broad range of patients: from metastatic pain, to Guillain-Barré syndrome, and diabetic neuropathy. Neurogenic inflammation is associated with CNP, 97 and animal models have shown IL-10 to reduce this inflammation and subsequently improve mechanical allodynia in painful diabetic neuropathy, 98 possibly suggesting a role for BTX-A in the treatment of CNP. BTX-A also regulates ion channel insertion in fibers of the trigeminal ganglion, suggesting particular benefit of the therapy for CM patients presenting with hyperalgesia and allodynia.…”

Section: Clinic Al Implic Ationsmentioning

confidence: 99%

The processes underlying chronic migraine pathophysiology and its treatment with botulinum toxin type A

Atraszkiewicz

2021

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

show abstract

Interleukin-10 Reduces Neurogenic Inflammation and Pain Behavior in a Mouse Model of Type 2 Diabetes

Cited by 19 publications

References 60 publications

Thymoquinone Modulates Local MMP-9, IL-10, and IgG in Sciatic Nerve Crush Injury Animal Model

Thymoquinone Modulates Local MMP-9, IL-10, and IgG in Sciatic Nerve Crush Injury Animal Model

Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model—In Vivo and In Vitro Study

The processes underlying chronic migraine pathophysiology and its treatment with botulinum toxin type A

Contact Info

Product

Resources

About